

Marcello Maida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4785851/publications.pdf>

Version: 2024-02-01

168
papers

5,416
citations

81900

39
h-index

95266

68
g-index

172
all docs

172
docs citations

172
times ranked

7486
citing authors

#	ARTICLE	IF	CITATIONS
1	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1274-1283.	7.3	374
2	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. <i>Hepatology</i> , 2011, 54, 2055-2063.	7.3	321
3	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	1.3	291
4	Neovascularization-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. <i>Gut</i> , 2016, 65, 861-869.	12.1	207
5	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	1.3	201
6	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
7	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	7.3	183
8	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1232-1244.	3.8	137
9	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	2.4	123
10	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	3.7	110
11	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. <i>Hepatology</i> , 2015, 62, 784-791.	7.3	110
12	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005, 42, 535-540.	3.7	101
13	Staging systems of hepatocellular carcinoma: A review of literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 4141.	3.3	94
14	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	7.3	93
15	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1046-1054.	7.3	89
16	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 1500-1509.	1.3	84
17	Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. <i>Journal of Hepatology</i> , 2016, 65, 861-862.	3.7	77
18	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011, 31, 507-515.	3.9	70

#	ARTICLE	IF	CITATIONS
19	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	3.9	70
20	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
21	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	3.7	67
22	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	3.9	67
23	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2012, 4, 256.	2.0	67
24	Multimodal approaches to the treatment of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 159-169.	17.8	66
25	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	3.3	66
26	Refining prognosis after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	3.9	62
27	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 385-399.	3.7	59
28	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.4	59
29	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	4.1	56
30	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 105-110.	3.7	56
31	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. <i>Digestive and Liver Disease</i> , 2020, 52, 808-815.	0.9	54
32	Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. <i>Scientific Reports</i> , 2018, 8, 12624.	3.3	50
33	Causes of and Prevention Strategies for Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 374-383.	2.2	49
34	Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey. <i>Digestive and Liver Disease</i> , 2020, 52, 1396-1402.	0.9	47
35	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	3.9	46
36	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014, 46, 1116-1120.	0.9	44

#	ARTICLE	IF	CITATIONS
37	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015, 47, 324-330.	0.9	43
38	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	3.7	42
39	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	3.9	41
40	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015, 11, 2923-2936.	2.4	40
41	Prognostic scores for hepatocellular carcinoma: none is the winner. <i>Liver International</i> , 2009, 29, 478-480.	3.9	39
42	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.	0.9	38
43	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Viruses</i> , 2022, 14, 986.	3.3	37
44	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	3.1	33
45	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2132.	3.3	32
46	Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance. <i>Digestive Diseases</i> , 2009, 27, 142-147.	1.9	31
47	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
48	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	1.9	30
49	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013, 5, 685.	2.0	29
50	Imaging appearance of treated hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2013, 5, 417.	2.0	29
51	Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. <i>PLoS ONE</i> , 2013, 8, e70016.	2.5	29
52	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	2.5	29
53	SARS-CoV-2 infection in patients with a normal or abnormal liver. <i>Journal of Viral Hepatitis</i> , 2021, 28, 4-11.	2.0	29
54	Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. <i>World Journal of Gastroenterology</i> , 2020, 26, 1950-1961.	3.3	29

#	ARTICLE	IF	CITATIONS
55	EUS-guided choledochoduodenostomy for malignant distal biliary obstruction after failed ERCP: a retrospective nationwide analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 896-904.e1.	1.0	29
56	Use of artificial intelligence in improving adenoma detection rate during colonoscopy: Might both endoscopists and pathologists be further helped. <i>World Journal of Gastroenterology</i> , 2020, 26, 5911-5918.	3.3	27
57	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. <i>BioMed Research International</i> , 2013, 2013, 1-12.	1.9	26
58	Treatment of hepatocellular carcinoma: present and future. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 469-479.	2.4	23
59	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. <i>Journal of Hepatology</i> , 2009, 51, 675-681.	3.7	22
60	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1807-1816.	2.4	22
61	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-7.	1.4	22
62	Should cirrhosis change our attitude towards treating non- α hepatic cancer?. <i>Liver International</i> , 2012, 32, 21-27.	3.9	21
63	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 831-845.	2.4	21
64	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	1.5	21
65	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. <i>Future Oncology</i> , 2019, 15, 3411-3422.	2.4	21
66	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	3.7	21
67	Needle track seeding following percutaneous procedures for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2009, 1, 62.	2.0	21
68	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 814-824.	3.7	20
69	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	1.5	20
70	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018, 38, 2108-2116.	3.9	20
71	Effectiveness and safety of underwater techniques in gastrointestinal endoscopy: a comprehensive review of the literature. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 37-51.	2.4	19
72	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	3.7	18

#	ARTICLE	IF	CITATIONS
73	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	1.9	17
74	Screening of gastrointestinal cancers during COVID-19: a new emergency. <i>Lancet Oncology</i> , The, 2020, 21, e338.	10.7	16
75	<i>rs58542926</i> is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	3.9	15
76	Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-5.	1.5	15
77	Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 223-235.	2.4	15
78	Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1355-1361.	2.4	14
79	Effectiveness and safety of NER1006 versus standard bowel preparations: A meta-analysis of randomized phase-3 clinical trials. <i>Digestive and Liver Disease</i> , 2020, 52, 833-839.	0.9	14
80	Definition of a hospital volume threshold to optimize outcomes after drainage of pancreatic fluid collections with lumen-apposing metal stents: a nationwide cohort study. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1158-1172.	1.0	14
81	Real-life multicentre study of lumen-apposing metal stent for EUS-guided drainage of pancreatic fluid collections. <i>Gut</i> , 2022, 71, 1050-1052.	12.1	14
82	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	4.4	13
83	Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey. <i>Endoscopy International Open</i> , 2020, 08, E525-E533.	1.8	13
84	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110106.	3.2	13
85	Microbiota Gut-Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease. <i>Life</i> , 2021, 11, 715.	2.4	13
86	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	1.3	13
87	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, 729-734.	0.9	12
88	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 603-610.	2.4	12
89	Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. <i>World Journal of Hepatology</i> , 2015, 7, 2053.	2.0	12
90	Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?. <i>Future Oncology</i> , 2015, 11, 2371-2373.	2.4	11

#	ARTICLE	IF	CITATIONS
91	Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Don't Forget the Role of Cyclosporin. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1594-E1595.	1.9	10
92	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015, 33, 668-674.	1.9	10
93	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 696.	2.0	9
94	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 217-221.	1.9	9
95	Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device—Initial observations. <i>European Journal of Radiology</i> , 2012, 81, 663-670.	2.6	8
96	Assessment of treatment response in hepatocellular carcinoma: a review of the literature. <i>Future Oncology</i> , 2013, 9, 845-854.	2.4	8
97	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 310-311.	3.7	8
98	Curative therapies for hepatocellular carcinoma: an update and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 169-175.	2.4	8
99	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. <i>Gut</i> , 2021, 70, 1241-1243.	12.1	8
100	A cost-effective plan for global testing - an infection rate stratified, algorithm guided, multiple-level, continuously pooled testing strategy. <i>Science of the Total Environment</i> , 2021, 765, 144251.	8.0	8
101	New endoscopy advances to refine adenoma detection rate for colorectal cancer screening: None is the winner. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 402-406.	2.0	8
102	Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. <i>Digestive and Liver Disease</i> , 2022, 54, 629-634.	0.9	8
103	Minor Hepatic Resection Using Heat Coagulative Necrosis. <i>American Surgeon</i> , 2009, 75, 1213-1219.	0.8	7
104	Faecal Microbiota Transplantation as Emerging Treatment in European Countries. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1050, 177-195.	1.6	7
105	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 851-863.	2.4	7
106	Tenapanor for the treatment of irritable bowel syndrome with constipation. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 473-479.	3.1	7
107	Could Chronic Idiopathic Intestinal Pseudo-Obstruction Be Related to Viral Infections?. <i>Journal of Clinical Medicine</i> , 2021, 10, 268.	2.4	7
108	Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. <i>Digestive and Liver Disease</i> , 2022, 54, 183-191.	0.9	7

#	ARTICLE	IF	CITATIONS
109	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- $\hat{\pm}$ inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017, 49, 157-162.	0.9	6
110	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. <i>Future Oncology</i> , 2018, 14, 3049-3058.	2.4	6
111	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
112	Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2021, 53, 1171-1177.	0.9	6
113	Minor hepatic resection using heat coagulative necrosis. <i>American Surgeon</i> , 2009, 75, 1213-9.	0.8	6
114	Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. <i>World Journal of Hepatology</i> , 2013, 5, 288.	2.0	5
115	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1291-1302.	2.4	4
116	COVID-19 vaccine: Call for employees in international transportation industries and international travelers as the first priority in global distribution. <i>Open Medicine (Poland)</i> , 2021, 16, 134-138.	1.3	4
117	Blood-based prognostic biomarkers in Crohn's Disease patients on biologics: a promising tool to predict endoscopic outcomes. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1133-1141.	3.1	4
118	Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 253-255.	0.9	4
119	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 336.	2.0	4
120	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016, 16, e31681.	0.2	4
121	Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1257-1257.	2.8	3
122	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> , 0, , .	1.3	3
123	Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. <i>World Journal of Gastroenterology</i> , 2020, 26, 5375-5386.	3.3	3
124	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.9	3
125	Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. <i>Gastroenterology Insights</i> , 2022, 13, 117-126.	1.2	3
126	Quality of endoscopic screening for colorectal cancer in Italy: A national survey. <i>Digestive and Liver Disease</i> , 2022, 54, 1410-1418.	0.9	3

#	ARTICLE	IF	CITATIONS
127	GI Training in the COVID-19 Era: A Problem of Global Concern. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3405-3406.	2.3	2
128	Effectiveness and Tolerability of Very-low Volume Preparation for Colonoscopy: A Narrative Review. <i>Current Drug Metabolism</i> , 2021, 22, 85-88.	1.2	2
129	Young gastrointestinal angle: E-learning in gastroenterology: Future is now. <i>United European Gastroenterology Journal</i> , 2021, 9, 635-637.	3.8	2
130	ID: 3523449 EUS-GUIDED GALLBLADDER DRAINAGE USING LUMEN-APPPOSING METAL STENT AS RESCUE TREATMENT FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A LARGE MULTICENTER EXPERIENCE. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB244-AB245.	1.0	2
131	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2
132	Emerging artificial intelligence applications in gastroenterology: A review of the literature. <i>Artificial Intelligence in Gastrointestinal Endoscopy</i> , 2020, 1, 6-18.	0.3	2
133	Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature. <i>World Journal of Gastrointestinal Endoscopy</i> , 2020, 12, 172-192.	1.2	2
134	Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	1.6	2
135	An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature. <i>Life</i> , 2021, 11, 1415.	2.4	2
136	Perceived Feasibility of Endoscopic Ultrasound-Guided Gastroenteric Anastomosis: An Italian Survey. <i>Medicina (Lithuania)</i> , 2022, 58, 532.	2.0	2
137	Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 147-150.	2.4	1
138	Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017. <i>Future Oncology</i> , 2017, 13, 1297-1300.	2.4	1
139	Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 307-309.	2.4	1
140	Digital single-operator cholangioscopy in treating difficult biliary stones: results from a multicenter experience. <i>Minerva Gastroenterology</i> , 2021, , .	0.5	1
141	New Therapeutic Molecules and their Metabolism in Gastroenterology. <i>Current Drug Metabolism</i> , 2020, 21, 246-246.	1.2	1
142	Use of catheter-based cholangioscopy in the diagnosis of indeterminate stenosis: a multi-centre experience. <i>Minerva Gastroenterology</i> , 2022, , .	0.5	1
143	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?. <i>Recenti Progressi in Medicina</i> , 2018, 109, 605-608.	0.8	1
144	Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment. <i>Digestive and Liver Disease</i> , 2014, 46, e35-e36.	0.9	0

#	ARTICLE	IF	CITATIONS
145	The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection. <i>Digestive and Liver Disease</i> , 2014, 46, e20.	0.9	0
146	P.05.51 REFRACTORY GAVE TREATED WITH RADIOFREQUENCY ABLATION BY THROUGH-THE-SCOPE CATHETER: THREE CASES OF COMPLETE RESPONSE. <i>Digestive and Liver Disease</i> , 2019, 51, e205.	0.9	0
147	P.05.24 WHAT DOES A ILEOCOLONIC WALL THICKENING MEAN? RESULTS FROM A RETROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e194.	0.9	0
148	OC.13.3 EFFECTIVENESS AND TOLERABILITY OF VERY LOWVOLUME PREPARATION FOR COLONOSCOPY: A PROSPECTIVE, MULTICENTER STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e113.	0.9	0
149	P.01.22 A NATIONAL SURVEY ON GASTROENTEROLOGY TRAINING IN ITALY: CURRENT LANDSCAPE AND FUTURE NEEDS. <i>Digestive and Liver Disease</i> , 2019, 51, e142.	0.9	0
150	145€fEffectiveness and Tolerability of Very Low-Volume Preparation for Colonoscopy: A Prospective, Multicenter Observational Study. <i>American Journal of Gastroenterology</i> , 2019, 114, S87-S88.	0.4	0
151	T05.01.13 EFFECTIVENESS AND SAFETY OF NER1006 VERSUS STANDARD BOWEL PREPARATIONS: A META-ANALYSIS OF THREE RANDOMISED PHASE 3 CLINICAL TRIALS. <i>Digestive and Liver Disease</i> , 2020, 52, S143-S144.	0.9	0
152	Incidence of hepatocellular carcinoma after HCV eradication: assessing the risk. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 255-256.	1.5	0
153	Model for end stage liver disease for prediction of mortality in people with cirrhosis. <i>The Cochrane Library</i> , 0, , .	2.8	0
154	BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Inflammatory Bowel Diseases</i> , 2021, 27, S58-S58.	1.9	0
155	BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Gastroenterology</i> , 2021, 160, S79.	1.3	0
156	New Therapeutic Molecules and their Metabolism in Gastroenterology- Part II. <i>Current Drug Metabolism</i> , 2021, 22, 84-84.	1.2	0
157	Su453 BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S DISEASE PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Gastroenterology</i> , 2021, 160, S-697-S-698.	1.3	0
158	ID: 3521184 EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMEN APPOSING METAL STENT FOR ACUTE CHOLECYSTITIS: RESULTS OF A MULTICENTER STUDY. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB268.	1.0	0
159	PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). <i>Digestive and Liver Disease</i> , 2021, 53, S88.	0.9	0
160	AF.141 EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMEN APPOSING METAL STENT FOR ACUTE CHOLECYSTITIS: RESULTS OF A MULTICENTER STUDY. <i>Digestive and Liver Disease</i> , 2021, 53, S201.	0.9	0
161	OC.09.8 BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Digestive and Liver Disease</i> , 2021, 53, S130-S131.	0.9	0
162	Upper gastrointestinal tract involvement in Crohn's disease: A relevant yet underestimated problem.. <i>Digestive and Liver Disease</i> , 2021, 53, 1546-1547.	0.9	0

#	ARTICLE	IF	CITATIONS
163	146 Safety of NER1006 in the Elderly: A Post-Hoc Analysis of a Prospective, Multicenter Cohort. American Journal of Gastroenterology, 2019, 114, S88-S88.	0.4	0
164	144 Efficacy and Safety of NER1006 Versus Standard Bowel Preparations: A Meta-Analysis of Randomized Phase 3 Clinical Trials. American Journal of Gastroenterology, 2019, 114, S85-S85.	0.4	0
165	Emerging artificial intelligence applications in gastroenterology: A review of the literature. Artificial Intelligence in Gastrointestinal Endoscopy, 2020, 1, 19-27.	0.3	0
166	Chemoprevention for hepatocellular carcinoma: the role of statins. Hepatobiliary Surgery and Nutrition, 2013, 2, 1-3.	1.5	0
167	Authors' reply to "Use of restrictive iron transfusion strategy in IBD: one size does not fit all". European Journal of Gastroenterology and Hepatology, 2022, Publish Ahead of Print, .	1.6	0
168	Surveillance strategies for precancerous gastric conditions after <i>Helicobacter pylori</i> eradication: There is still need for a tailored approach. World Journal of Gastroenterology, 2021, 27, 8033-8039.	3.3	0